NasdaqGS:ABCLLife Sciences
AbCellera (ABCL) Is Up 18.8% After Pivoting To Clinical Stage And Filing Share Offering
AbCellera Biologics Inc. has reported its full-year 2025 results, with revenue rising to US$75.13 million and net loss easing to US$146.41 million, while also filing a US$45.54 million shelf registration for 15,030,034 common shares tied to an employee share offering.
Alongside these financials, AbCellera’s shift into a clinical-stage biotech with advancing programs ABCL635 and ABCL575 and a nearly completed manufacturing facility signals a business model increasingly centered on internal...